Pharmacogenetics and pharmacogenomics are areas of rapidly growing importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs; it reviews advances in the field and describes the findings that have already emerged.

Coverage extends to antipsychotics, antidepressants, mood-stabilizing, cognitive-enhancing, and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider the impact of pharmacogenetics on the biotechnology and pharmaceutical industries.

This book defines the young field of pharmacogenetics as it applies to psychotropic drugs and is, therefore, an essential reference for all clinicians and researchers working in this field.

Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah-Hebrew University Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.
Pharmacogenetics of Psychotropic Drugs

Edited by

Bernard Lerer

Hadassah-Hebrew University Medical Center, Jerusalem, Israel
## Contents

**List of contributors**  
*page viii*

### Part I  Introduction

1. Genes and psychopharmacology: exploring the interface  
   Bernard Lerer  
   *page 3*

### Part II  Clinical background and research design

2. From pharmacogenetics to pharmacogenomics of psychotropic drug response  
   Anil K. Malhotra  
   *page 21*

3. Neuropsychopharmacology: the interface between genes and psychiatric nosology  
   Thomas A. Ban  
   *page 36*

4. Methodological issues in psychopharmacogenetics  
   Sheldon H. Preskorn  
   *page 57*

5. Statistical approaches in psychopharmacogenetics  
   Fabio Macciardi  
   *page 72*

### Part III  Molecular background

6. The psychopharmacogenetic–neurodevelopmental interface in serotonergic gene pathways  
   K. Peter Lesch, Jens Benninghoff, and Angelika Schmitt  
   *page 95*
<table>
<thead>
<tr>
<th>Part IV</th>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Pharmacogenetics of psychotropic drug metabolism</td>
</tr>
<tr>
<td></td>
<td>Vural Ozdemir, Angela D.M. Kashuba, Vincenzo S. Basile, and James L. Kennedy</td>
</tr>
<tr>
<td>9</td>
<td>Pharmacogenetics of chiral psychotropic drugs</td>
</tr>
<tr>
<td></td>
<td>Pierre Baumann and Chin B. Eap</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part V</th>
<th>Specific psychotropic drugs and disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Clozapine response and genetic variation in neurotransmitter receptor targets</td>
</tr>
<tr>
<td></td>
<td>David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama, and Robert W. Kerwin</td>
</tr>
<tr>
<td>11</td>
<td>Genetic factors underlying drug-induced tardive dyskinesia</td>
</tr>
<tr>
<td></td>
<td>Ronnen H. Segman and Bernard Lerer</td>
</tr>
<tr>
<td>12</td>
<td>Functional gene-linked polymorphic regions in pharmacogenetics</td>
</tr>
<tr>
<td></td>
<td>Marco Catalano</td>
</tr>
<tr>
<td>13</td>
<td>Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders</td>
</tr>
<tr>
<td></td>
<td>Emanuela Mundo and James L. Kennedy</td>
</tr>
<tr>
<td>14</td>
<td>Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex</td>
</tr>
<tr>
<td></td>
<td>Smita A. Pandit, Spilios V. Argyropoulos, Patrick G. Kehoe, and David J. Nutt</td>
</tr>
<tr>
<td>15</td>
<td>Genetic factors and long-term prophylaxis in bipolar disorder</td>
</tr>
<tr>
<td></td>
<td>Martin Alda</td>
</tr>
<tr>
<td>16</td>
<td>Genetic influences on responsiveness to anticonvulsant drugs</td>
</tr>
<tr>
<td></td>
<td>Thomas N. Ferraro</td>
</tr>
<tr>
<td>17</td>
<td>Apolipoprotein E as a marker in the treatment of Alzheimer’s disease</td>
</tr>
<tr>
<td></td>
<td>Keith Schappert, Pierre Sevigny, and Judes Poirier</td>
</tr>
</tbody>
</table>

vi  Contents

7  RNA processing regulation and interindividual variation  127
Colleen M. Niswender and Linda K. Hutchinson

8  Pharmacogenetics of psychotropic drug metabolism  157
Vural Ozdemir, Angela D.M. Kashuba, Vincenzo S. Basile, and James L. Kennedy

9  Pharmacogenetics of chiral psychotropic drugs  181
Pierre Baumann and Chin B. Eap

10 Clozapine response and genetic variation in neurotransmitter receptor targets  217
David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama, and Robert W. Kerwin

11 Genetic factors underlying drug-induced tardive dyskinesia  245
Ronnbn H. Segman and Bernard Lerer

12 Functional gene-linked polymorphic regions in pharmacogenetics  267
Marco Catalano

13 Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders  283
Emanuela Mundo and James L. Kennedy

14 Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex  300
Smita A. Pandit, Spilios V. Argyropoulos, Patrick G. Kehoe, and David J. Nutt

15 Genetic factors and long-term prophylaxis in bipolar disorder  320
Martin Alda

16 Genetic influences on responsiveness to anticonvulsant drugs  333
Thomas N. Ferraro

17 Apolipoprotein E as a marker in the treatment of Alzheimer’s disease  360
Keith Schappert, Pierre Sevigny, and Judes Poirier
### Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Genetic variation and drug dependence risk factors</td>
<td>Joel Gelernter and Henry Kranzler</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Part VI Pharmacogenetics and brain imaging</strong></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Brain imaging and pharmacogenetics in Alzheimer’s disease and schizophrenia</td>
<td>Steven G. Potkin, James L. Kennedy, and Vincenzo S. Basile</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Part VII Industry perspectives</strong></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Pharmacogenetics in psychotropic drug discovery and development</td>
<td>William Z. Potter, AnnCatherine Van Lone, and Larry Altstiel</td>
</tr>
<tr>
<td>21</td>
<td>High-throughput single nucleotide polymorphism genotyping</td>
<td>Anne Shalom and Ariel Darvasi</td>
</tr>
</tbody>
</table>

*Index* 439
Contributors

Martin Alda
Department of Psychiatry, Dalhousie University, Abbie J. Lane Building, 5909 Jubilee Rd, Halifax, Nova Scotia, B3H 2E2, Canada

Larry Altsteil
Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, NJ 07033-1300, USA

Spilios V. Argyropoulos
Psychopharmacology Unit, University of Bristol, University Walk, Bristol BS8 1TD, UK

Maria J. Arranz
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Thomas A. Ban
Vanderbilt University, Nashville, TN, USA

Vincenzo S. Basile
Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Pierre Baumann
Department Universitaire de Psychiatrie Adulte, Adulte Hopital de Cery, CH-1008 Prilly, Switzerland

Jens Benninghoff
Department of Psychiatry, University of Wurzburg, Fuchsleinstr. 15, 97080 Wurzburg, Germany

Marco Catalano
IRCCS H. San Raffaele, Department of Neuropsychiatric Sciences, Milan, Italy

David A. Collier
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Ariel Darvasi
The Life Sciences Institute, The Hebrew University of Jerusalem and IDgene Pharmaceuticals, Jerusalem 91904, Israel

Chin B. Eap
Department Universitaire de Psychiatrie Adulte, Adulte Hopital de Cery, CH-1008 Prilly, Switzerland

Thomas N. Ferraro
Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, 415 Curie Blvd, Philadelphia, PA 19104, USA
List of contributors

Joel Gelernter  
Department of Psychiatry, Yale University  
School of Medicine, New Haven, CT 06516, USA

Linda K. Hutchinson  
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA

Angela D.M. Kashuba  
School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

Patrick G. Kehoe  
Psychopharmacology Unit, University of Bristol, University Walk, Bristol, BS8 1TD, UK

James L. Kennedy  
Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Robert W. Kerwin  
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Henry Kranzler  
Department of Psychiatry, University of Connecticut, School of Medicine, Farmington, CT, USA

Bernard Lerer  
Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah-Hebrew University Medical Center, Ein Karem, Jerusalem 91120, Israel

K. Peter Lesch  
Department of Psychiatry, University of Wurzburg, Fuchsleinstr. 15, 97080 Wurzburg, Germany

Fabio Macciardi  
Unit of Biostatistics and Genetic Epidemiology, Neurogenetics Section, Clarke Division, Center for Addiction and Mental Health, R-32, 250 College Street, Toronto, Ontario, M5T 1R8, Canada

Anil K. Malhotra  
Unit of Molecular Psychiatry, Hillside Hospital, 75–59 263rd St, Glen Oaks, NY 11004, USA

Dalu Mancama  
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Emanuela Mundo  
Department of Psychiatry, University of Wurzburg, Fuchsleinstr. 15, 97080 Wurzburg, Germany

Janet Munro  
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Colleen M. Niswender  
Department of Pharmacology, University of Washington, Seattle, WA 98195, USA

David J. Nutt  
Psychopharmacology Unit, University of Bristol, University Walk, Bristol, BS8 1TD, UK

Sarah Osborne  
Institute of Psychiatry, De Crespigy Park, Denmark Hill, London SE5 8AF, UK

Vural Ozdemir  
Department of Pharmacogenomics, Drug Discovery Division, R.W. Johnson Pharmaceutical Research Institute, Route 202 South, #1000 OMP Building, Raritan, NJ 08869, USA
List of contributors

Smita A. Pandit
Psychopharmacology Unit, University of Bristol, University Walk, Bristol, BS8 1TD, UK

Judes Poirier
Center for Studies in Aging, 6875 Blvd. Lasalle, Verdun, Quebec, H4H 1R3, Canada

Steven G. Potkin
Brain Imaging Center, University of California, Irvine Hall, Irvine, CA 92697–3960, USA

William Z. Potter
Lilly Research Laboratory, Lilly Corporate Center, Drop Code 0532, Indianapolis, IA 46285, USA

Sheldon H. Preskorn
Psychiatric Research Institute, University of Kansas, 1100 N. St Francis, Wichita, KS 67214, USA

Keith Schappert
Mirador DNA Design, Suite 501, 404 McGill St, Montreal, Quebec H2Y 2G1, Canada

Angelina Schmitt
Department of Psychiatry, University of Wurzburg, Fuchsleinstr. 15, 97080 Wurzburg, Germany

Ronen H. Segman
Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah-Hebrew University Medical Center, Ein Karem, Jerusalem 91120, Israel

Pierre Savigny
Mirador DNA Design, Suite 501, 404 McGill St, Montreal, Quebec H2Y 2G1, Canada

Anne Shalom
The Life Sciences Institute, The Hebrew University of Jerusalem, Israel

AnnCatherine Van Lone
Lilly Research Laboratory, Lilly Corporate Center, Drop Code 0532, Indianapolis, IA 46285, USA